Vaxartto Present at World Vaccine Congress Washington 2025 on April 23
Vaxart (Nasdaq: VXRT) has announced its participation in the World Vaccine Congress Washington 2025, scheduled for April 23, 2025, in Washington, D.C. Two key executives will deliver presentations at the event:
Dr. James F. Cummings, Chief Medical Officer, will present on 'Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination' at 1:10 p.m. ET in Room 207A.
Dr. Sean Tucker, Founder and Chief Scientific Officer, will discuss 'Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection' at 3:10 p.m. ET in the same room. The company has been a regular presenter at this annual Washington, D.C. event.
Vaxart (Nasdaq: VXRT) ha annunciato la sua partecipazione al World Vaccine Congress Washington 2025, previsto per il 23 aprile 2025 a Washington, D.C. Due dirigenti chiave terranno presentazioni durante l'evento:
Il dott. James F. Cummings, Chief Medical Officer, parlerà alle 13:10 ET nella Sala 207A su "Far progredire la ricerca: bloccare la trasmissione e potenziare i vaccini esistenti con la vaccinazione orale in compresse".
Il dott. Sean Tucker, Fondatore e Chief Scientific Officer, discuterà alle 15:10 ET nella stessa sala su "Profilazione immunitaria di un candidato vaccino orale contro il norovirus; correlati di protezione contro malattia e infezione". L'azienda è una presenza abituale a questo evento annuale di Washington, D.C.
Vaxart (Nasdaq: VXRT) ha anunciado su participación en el World Vaccine Congress Washington 2025, programado para el 23 de abril de 2025 en Washington, D.C. Dos ejecutivos clave ofrecerán presentaciones en el evento:
El Dr. James F. Cummings, Director Médico, presentará a la 1:10 p.m. ET en la Sala 207A sobre "Avanzando: Bloqueo de la transmisión y potenciación de las vacunas existentes mediante vacunación oral en tabletas".
El Dr. Sean Tucker, Fundador y Director Científico, hablará a las 3:10 p.m. ET en la misma sala sobre "Perfil inmunológico de un candidato a vacuna oral contra el norovirus; correlatos de protección para enfermedad e infección". La compañía ha sido un presentador habitual en este evento anual en Washington, D.C.
Vaxart (나스닥: VXRT)는 2025년 4월 23일 워싱턴 D.C.에서 열리는 World Vaccine Congress Washington 2025에 참가한다고 발표했습니다. 두 명의 주요 임원이 행사에서 발표를 진행합니다:
James F. Cummings 박사(최고 의료 책임자)는 동부 표준시 오후 1시 10분, 207A호실에서 '변화를 이끄는 힘: 경구용 정제 백신으로 전파 차단 및 기존 백신 강화'에 대해 발표합니다.
Sean Tucker 박사(창립자 겸 최고 과학 책임자)는 같은 방에서 동부 표준시 오후 3시 10분에 '경구용 노로바이러스 백신 후보의 면역 프로파일링; 질병 및 감염에 대한 보호 상관관계'를 주제로 강연합니다. 이 회사는 워싱턴 D.C.에서 매년 열리는 이 행사에 정기적으로 참여해 왔습니다.
Vaxart (Nasdaq : VXRT) a annoncé sa participation au World Vaccine Congress Washington 2025, prévu le 23 avril 2025 à Washington, D.C. Deux cadres clés présenteront lors de l'événement :
Le Dr James F. Cummings, directeur médical, interviendra à 13h10 ET dans la salle 207A sur le thème « Faire avancer les choses : bloquer la transmission et renforcer les vaccins existants grâce à la vaccination orale par comprimé ».
Le Dr Sean Tucker, fondateur et directeur scientifique, abordera à 15h10 ET dans la même salle « Profil immunitaire d’un candidat vaccin oral contre le norovirus ; corrélats de protection contre la maladie et l’infection ». L’entreprise est un participant régulier de cet événement annuel à Washington, D.C.
Vaxart (Nasdaq: VXRT) hat seine Teilnahme am World Vaccine Congress Washington 2025 angekündigt, der am 23. April 2025 in Washington, D.C. stattfindet. Zwei wichtige Führungskräfte werden auf der Veranstaltung Vorträge halten:
Dr. James F. Cummings, Chief Medical Officer, wird um 13:10 Uhr ET im Raum 207A zum Thema „Fortschritte erzielen: Übertragung blockieren und bestehende Impfstoffe durch orale Tablettenimpfung stärken“ sprechen.
Dr. Sean Tucker, Gründer und Chief Scientific Officer, wird um 15:10 Uhr ET im selben Raum über „Immunprofilierung eines oralen Norovirus-Impfstoffkandidaten; Schutzkorrelate für Krankheit und Infektion“ referieren. Das Unternehmen ist regelmäßiger Teilnehmer dieser jährlichen Veranstaltung in Washington, D.C.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C.
Presentation Information:
Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination
Speaker: Dr. James F. Cummings
Date: Wednesday, April 23, 2025
Time: 1:10 p.m. ET
Room: 207A
Title: Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection
Speaker: Dr. Sean Tucker
Date: Wednesday, April 23, 2024
Time: 3:10 p.m. ET
Room: 207A
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
FAQ
What presentations will Vaxart (VXRT) give at the World Vaccine Congress 2025?
When and where is Vaxart (VXRT) presenting at the World Vaccine Congress 2025?
What is Vaxart's (VXRT) focus for their oral vaccine presentation at the 2025 Congress?
What research will Dr. Sean Tucker present for Vaxart (VXRT) at the 2025 Congress?
